Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 3/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | RARG | P13631 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388073 | 0.86 | NR1H4 (0.54) | MAPTALDH1A1NPC1HSD17B10RAB9A | |
| SCHEMBL388747 | 0.85 | NR1H4 (0.60) | MAPTALDH1A1NPC1HSD17B10KDM4E | |
| SCHEMBL389684 | 0.85 | NR1H4 (0.53) | KMT2ANPC1RAB9ANR1H4S1PR1 | |
| SCHEMBL387937 | 0.84 | NR1H4 (0.59) | MAPTALDH1A1NPC1HSD17B10TP53 | |
| SCHEMBL384837 | 0.84 | NR1H4 (0.52) | ALDH1A1KMT2ANPC1HSD17B10TP53 | |
| SCHEMBL388070 | 0.84 | NR1H4 (0.52) | MEN1KMT2ANPC1RAB9ANR1H4 | |
| SCHEMBL12171461 | 0.83 | NPC1 (0.57) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL388243 | 0.83 | NR1H4 (0.52) | MAPTALDH1A1NPC1TP53HPGD | |
| SCHEMBL384625 | 0.81 | CA12 (0.51) | MAPTNPC1RAB9ANR1H4S1PR1 | |
| SCHEMBL388748 | 0.81 | CHUK (0.55) | NR1H4S1PR1RARBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | claimed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | UPF1, RIOX2, RNMT | MAPT 4451/4885MEN1 4772/4885ALDH1A1 1460/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | MAPT 4413/4885MEN1 4752/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.